CERo Pb Ratio vs Capex To Operating Cash Flow Analysis

CEROW Stock

0.01 0 13.27%

CERo Therapeutics financial indicator trend analysis is way more than just evaluating CERo Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CERo Therapeutics is a good investment. Please check the relationship between CERo Therapeutics Pb Ratio and its Capex To Operating Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CERo Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

Pb Ratio vs Capex To Operating Cash Flow

Pb Ratio vs Capex To Operating Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CERo Therapeutics Pb Ratio account and Capex To Operating Cash Flow. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between CERo Therapeutics' Pb Ratio and Capex To Operating Cash Flow is -0.2. Overlapping area represents the amount of variation of Pb Ratio that can explain the historical movement of Capex To Operating Cash Flow in the same time period over historical financial statements of CERo Therapeutics Holdings, assuming nothing else is changed. The correlation between historical values of CERo Therapeutics' Pb Ratio and Capex To Operating Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pb Ratio of CERo Therapeutics Holdings are associated (or correlated) with its Capex To Operating Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Operating Cash Flow has no effect on the direction of Pb Ratio i.e., CERo Therapeutics' Pb Ratio and Capex To Operating Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.2

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Pb Ratio

Capex To Operating Cash Flow

Most indicators from CERo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CERo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CERo Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

Selling General Administrative is likely to drop to 2,748 in 2024. Enterprise Value Over EBITDA is likely to drop to -31.51 in 2024

	2010	2022	2023	2024 (projected)
Interest Income	986.7K	142.1K	127.9K	121.5K
Net Interest Income	986.7K	142.1K	127.9K	121.5K

Interest Income Net Interest Income

CERo Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Net Working Capital
Total Assets		0.95	-0.44	-0.62	1.0	0.95	-0.98	0.47	0.97	-0.89	-0.41	0.99	0.8	0.98	-0.41	0.98	-0.79	0.99	-0.85	0.53	-0.88	0.96	-0.87	-0.63	-0.85	0.97
Short Long Term Debt Total	0.95		-0.69	-0.83	0.97	0.83	-0.99	0.71	0.86	-0.7	-0.67	0.98	0.61	0.99	-0.67	0.98	-0.6	0.91	-0.64	0.24	-0.98	1.0	-0.7	-0.84	-0.66	0.98
Other Current Liab	-0.44	-0.69		0.98	-0.49	-0.18	0.61	-1.0	-0.22	-0.03	1.0	-0.53	0.1	-0.59	1.0	-0.57	-0.1	-0.34	-0.11	0.54	0.81	-0.65	-0.01	0.97	-0.06	-0.58
Total Current Liabilities	-0.62	-0.83	0.98		-0.67	-0.39	0.77	-0.98	-0.43	0.19	0.97	-0.71	-0.11	-0.75	0.97	-0.74	0.11	-0.54	0.11	0.34	0.91	-0.8	0.21	1.0	0.16	-0.74
Total Stockholder Equity	1.0	0.97	-0.49	-0.67		0.94	-0.99	0.52	0.96	-0.86	-0.46	1.0	0.77	0.99	-0.46	0.99	-0.76	0.99	-0.81	0.47	-0.91	0.98	-0.84	-0.68	-0.82	0.98
Property Plant And Equipment Net	0.95	0.83	-0.18	-0.39	0.94		-0.88	0.21	0.99	-0.97	-0.15	0.92	0.94	0.89	-0.15	0.88	-0.83	0.98	-0.95	0.72	-0.73	0.87	-0.91	-0.4	-0.9	0.85
Current Deferred Revenue	-0.98	-0.99	0.61	0.77	-0.99	-0.88		-0.63	-0.91	0.78	0.58	-1.0	-0.68	-1.0	0.58	-0.99	0.68	-0.95	0.72	-0.35	0.96	-1.0	0.77	0.77	0.74	-0.99
Net Debt	0.47	0.71	-1.0	-0.98	0.52	0.21	-0.63		0.25	0.0	-1.0	0.56	-0.07	0.62	-1.0	0.6	0.07	0.37	0.08	-0.51	-0.82	0.67	-0.02	-0.98	0.03	0.61
Retained Earnings	0.97	0.86	-0.22	-0.43	0.96	0.99	-0.91	0.25		-0.97	-0.19	0.94	0.91	0.91	-0.19	0.92	-0.86	0.99	-0.95	0.71	-0.75	0.88	-0.93	-0.44	-0.92	0.89
Accounts Payable	-0.89	-0.7	-0.03	0.19	-0.86	-0.97	0.78	0.0	-0.97		-0.06	-0.83	-0.95	-0.79	-0.06	-0.8	0.92	-0.93	1.0	-0.86	0.57	-0.74	0.97	0.2	0.97	-0.77
Cash	-0.41	-0.67	1.0	0.97	-0.46	-0.15	0.58	-1.0	-0.19	-0.06		-0.5	0.13	-0.57	1.0	-0.54	-0.13	-0.31	-0.14	0.56	0.79	-0.63	-0.04	0.96	-0.09	-0.56
Non Current Assets Total	0.99	0.98	-0.53	-0.71	1.0	0.92	-1.0	0.56	0.94	-0.83	-0.5		0.74	1.0	-0.5	0.99	-0.73	0.98	-0.78	0.43	-0.93	0.99	-0.82	-0.71	-0.79	0.98
Non Currrent Assets Other	0.8	0.61	0.1	-0.11	0.77	0.94	-0.68	-0.07	0.91	-0.95	0.13	0.74		0.69	0.13	0.68	-0.76	0.86	-0.95	0.84	-0.5	0.67	-0.84	-0.12	-0.84	0.63
Other Assets	0.98	0.99	-0.59	-0.75	0.99	0.89	-1.0	0.62	0.91	-0.79	-0.57	1.0	0.69		-0.57	1.0	-0.7	0.96	-0.74	0.36	-0.95	0.99	-0.78	-0.76	-0.75	0.99
Cash And Short Term Investments	-0.41	-0.67	1.0	0.97	-0.46	-0.15	0.58	-1.0	-0.19	-0.06	1.0	-0.5	0.13	-0.57		-0.54	-0.13	-0.31	-0.14	0.56	0.79	-0.63	-0.04	0.96	-0.09	-0.56
Common Stock Shares Outstanding	0.98	0.98	-0.57	-0.74	0.99	0.88	-0.99	0.6	0.92	-0.8	-0.54	0.99	0.68	1.0	-0.54		-0.74	0.96	-0.75	0.39	-0.93	0.98	-0.81	-0.74	-0.78	1.0
Non Current Liabilities Total	-0.79	-0.6	-0.1	0.11	-0.76	-0.83	0.68	0.07	-0.86	0.92	-0.13	-0.73	-0.76	-0.7	-0.13	-0.74		-0.83	0.92	-0.84	0.44	-0.61	0.99	0.12	0.99	-0.74
Capital Lease Obligations	0.99	0.91	-0.34	-0.54	0.99	0.98	-0.95	0.37	0.99	-0.93	-0.31	0.98	0.86	0.96	-0.31	0.96	-0.83		-0.9	0.61	-0.83	0.93	-0.9	-0.55	-0.89	0.94
Other Current Assets	-0.85	-0.64	-0.11	0.11	-0.81	-0.95	0.72	0.08	-0.95	1.0	-0.14	-0.78	-0.95	-0.74	-0.14	-0.75	0.92	-0.9		-0.9	0.5	-0.68	0.96	0.12	0.97	-0.72
Other Stockholder Equity	0.53	0.24	0.54	0.34	0.47	0.72	-0.35	-0.51	0.71	-0.86	0.56	0.43	0.84	0.36	0.56	0.39	-0.84	0.61	-0.9		-0.07	0.29	-0.83	0.33	-0.86	0.36
Total Liab	-0.88	-0.98	0.81	0.91	-0.91	-0.73	0.96	-0.82	-0.75	0.57	0.79	-0.93	-0.5	-0.95	0.79	-0.93	0.44	-0.83	0.5	-0.07		-0.97	0.55	0.92	0.51	-0.92
Net Invested Capital	0.96	1.0	-0.65	-0.8	0.98	0.87	-1.0	0.67	0.88	-0.74	-0.63	0.99	0.67	0.99	-0.63	0.98	-0.61	0.93	-0.68	0.29	-0.97		-0.71	-0.81	-0.68	0.97
Property Plant And Equipment Gross	-0.87	-0.7	-0.01	0.21	-0.84	-0.91	0.77	-0.02	-0.93	0.97	-0.04	-0.82	-0.84	-0.78	-0.04	-0.81	0.99	-0.9	0.96	-0.83	0.55	-0.71		0.22	1.0	-0.81
Total Current Assets	-0.63	-0.84	0.97	1.0	-0.68	-0.4	0.77	-0.98	-0.44	0.2	0.96	-0.71	-0.12	-0.76	0.96	-0.74	0.12	-0.55	0.12	0.33	0.92	-0.81	0.22		0.17	-0.75
Capital Stock	-0.85	-0.66	-0.06	0.16	-0.82	-0.9	0.74	0.03	-0.92	0.97	-0.09	-0.79	-0.84	-0.75	-0.09	-0.78	0.99	-0.89	0.97	-0.86	0.51	-0.68	1.0	0.17		-0.77
Net Working Capital	0.97	0.98	-0.58	-0.74	0.98	0.85	-0.99	0.61	0.89	-0.77	-0.56	0.98	0.63	0.99	-0.56	1.0	-0.74	0.94	-0.72	0.36	-0.92	0.97	-0.81	-0.75	-0.77

Click cells to compare fundamentals

CERo Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for CERo Stock Analysis

When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CERo Pb Ratio vs Capex To Operating Cash Flow Analysis

Pb Ratio vs Capex To Operating Cash Flow

Pb Ratio vs Capex To Operating Cash Flow Correlation Analysis

Correlation Coefficient

Pb Ratio

Capex To Operating Cash Flow

CERo Therapeutics fundamental ratios Correlations

CERo Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for CERo Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Short Long Term Debt Total
Cash	+ 1.0	Other Current Liab
Cash And Short Term Investments	+ 1.0	Other Current Liab
Total Current Assets	+ 1.0	Total Current Liabilities
Non Current Assets Total	+ 1.0	Total Stockholder Equity

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Invested Capital	- 1.0	Current Deferred Revenue
Other Assets	- 1.0	Current Deferred Revenue
Non Current Assets Total	- 1.0	Current Deferred Revenue
Net Debt	- 1.0	Other Current Liab